Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
MCMedscape Cardiology
“We shouldn't choose between neprilysin inhibition [sacubitril inhibits the enzyme neprilysin] and SGLT2 [sodium-glucose transporter 2] inhibition; we should use both.”
Implication
Key Points
Key points are not available for this paper at this time.
Cite This Study
Packer et al. (2020) studied this question.